NCT03288103View on ClinicalTrials.gov

Growth Hormone Treatment in Patients With Aggrecan (ACAN) Deficiency

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

February 1, 2018

Primary Completion Date

March 31, 2023

Study Completion Date

August 31, 2023

Conditions
Short Stature
Interventions
DRUG

Norditropin

Single dose of daily growth hormone regimen. Dose will be 50 micrograms/kg/day.

Trial Locations (1)

45229

Cincinnati Childrens Hospital Medical Center, Cincinnati

All Listed Sponsors
lead

Children's Hospital Medical Center, Cincinnati

OTHER

NCT03288103 - Growth Hormone Treatment in Patients With Aggrecan (ACAN) Deficiency | Biotech Hunter | Biotech Hunter